Wyeth Hears Echo Of Managed Care In Medicare: “Minor Negative” At First
Executive Summary
Wyeth believes the implementation of the Medicare prescription drug benefit is likely to parallel the impact of the emergence of managed care on the pharmaceutical industry
You may also be interested in...
Lilly Sees Benefit From Medicare Rx In Short Term, But Risk For Zyprexa
Lilly expects a "modest benefit" from implementation of Medicare Part D that could later be offset by increased pricing pressures
Lilly Sees Benefit From Medicare Rx In Short Term, But Risk For Zyprexa
Lilly expects a "modest benefit" from implementation of Medicare Part D that could later be offset by increased pricing pressures
Wyeth More Optimistic About Medicare Rx; Protonix May Benefit
Wyeth is becoming more optimistic about the potential upside of the Medicare prescription drug benefit, Wyeth North America President Joseph Mahady said during the Smith Barney Citigroup Healthcare Conference in Washington, D.C. March 30